What does CUSIP 68232V884 represent in this 13F holders report?

CUSIP 68232V884 is the security identifier for TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share used to aggregate holder disclosures.

How many institutions held TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in Q4 2025?

21 institutional investors reported TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share for Q4 2025. Use the holders table for investor-level position and value details.

Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW)

CUSIP: 68232V884

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common stock, par value $.01 per share
Shares outstanding: 8,133,373
Total 13F shares: 3,418,588
Share change: +1,351,193
Total reported value: $3,863,003
Price per share: $1.13
Number of holders: 21
Value change: +$1,409,923
Number of buys: 12
Number of sells: 7

Quarterly Holders Quick Answers

What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 68232V884:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Top shareholders of TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	13D/G	—	10%	886,887	$1,641,628	+$632,468	30 Sep 2025	13D/G
Viriom, Inc.	3/4/5	10%+ Owner	— class O/S missing	1,645,100	$1,480,590	—	03 Apr 2024	3/4/5
Ikarian Capital, LLC	13D/G 13F	Company	10%	812,524	$1,308,164	+$359,065	31 Dec 2025	13D/G 13F
Adage Capital Management, L.P.	13D/G	—	9.1%	730,000	$1,175,300	+$644,000	31 Dec 2025	13D/G
ORBIMED ADVISORS LLC	13D/G 13F	Company	20%	760,824	$1,164,061	$0	31 Dec 2024	13D/G 13F
Squadron Capital Management LLC	13D/G	Squadron Master Fund LP	8.9%	713,540	$1,148,799	+$197,289	31 Dec 2025	13D/G
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	4.1%	330,000	$610,500	—	30 Sep 2025	13F
Ayrton Capital LLC	13D/G	—	4.3%	342,935	$552,125	-$97,751	31 Dec 2025	13D/G
Alyeska Investment Group, L.P.	13D/G	—	9.9%	302,252	$462,446	$0	31 Dec 2024	13D/G
Vestal Point Capital, LP	13F	Company	1.8%	150,000	$277,500	—	30 Sep 2025	13F
VANGUARD GROUP INC	13F	Company	1.1%	87,259	$161,429	—	30 Sep 2025	13F
Steven M. Fruchtman	3/4/5	PRESIDENT, CHIEF EXECUTIVE OFF, Director	— mixed-class rows	121,014 mixed-class rows	$98,282	—	13 Mar 2024	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.53%	43,440	$80,366	—	30 Sep 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.27%	22,018	$40,733	—	30 Sep 2025	13F
Abraham N. Oler	3/4/5	SVP Corp Dev & Gen Counsel	— mixed-class rows	96,197 mixed-class rows	$36,818	—	07 Feb 2022	3/4/5
Charles N. Parker	3/4/5	Chief Financial Officer	— mixed-class rows	119,937 mixed-class rows	$24,628	—	12 Oct 2025	3/4/5
Mark Patrick Guerin	3/4/5	Chief Financial Officer	— mixed-class rows	44,755 mixed-class rows	$23,400	—	05 Feb 2025	3/4/5
HRT FINANCIAL LP	13F	Company	0.15%	12,573	$23,000	—	30 Sep 2025	13F
XTX Topco Ltd	13F	Company	0.13%	10,708	$19,810	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.12%	9,956	$18,419	—	30 Sep 2025	13F
Mark S. Gelder MD	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	82,667 mixed-class rows	$13,847	—	13 Mar 2023	3/4/5
CITIGROUP INC	13F	Company	0.04%	3,528	$6,527	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0.01%	719	$1,330	—	30 Sep 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	162	$300	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	102	$189	—	30 Sep 2025	13F
Vermillion & White Wealth Management Group, LLC	13F	Company	0%	96	$178	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0%	6	$11	—	30 Sep 2025	13F
ASSETMARK, INC	13F	Company	0%	2	$4	—	30 Sep 2025	13F
FMR LLC	13F	Company	0%	2	$4	—	30 Sep 2025	13F
TPAV, LLC	3/4/5	10%+ Owner	— mixed-class rows	192,696 mixed-class rows	—	—	02 Apr 2025	3/4/5
Luba Greenwood	3/4/5	Director	— class O/S missing	164,000	—	—	16 Sep 2024	3/4/5
Victor M. Moyo	3/4/5	CHIEF MEDICAL OFFICER	— class O/S missing	125,000	—	—	02 Oct 2023	3/4/5
James J. Marino	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Jerome Groopman	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Peter Atadja	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5
Viren Mehta	3/4/5	Director	— class O/S missing	66,468	—	—	10 Aug 2023	3/4/5

Institutional Holders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) as of Q4 2025

As of 31 Dec 2025, Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,418,588 shares. The largest 10 holders included ADAGE CAPITAL PARTNERS GP, L.L.C., Squadron Capital Management LLC, Ikarian Capital, LLC, ORBIMED ADVISORS LLC, BOOTHBAY FUND MANAGEMENT, LLC, ADAR1 Capital Management, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Seven Fleet Capital Management LP, and XTX Topco Ltd. This page lists 21 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.